Pituitary-independent effect of octreotide on IGF1 generation

Ana Pokrajac; Jan Frystyk; Allan Flyvbjerg; Peter J. Trainer

doi:10.1530/EJE-08-0822

Pituitary-independent effect of octreotide on IGF1 generation

Ana Pokrajac, Jan Frystyk, Allan Flyvbjerg, Peter J. Trainer

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH

Original language	English
Pages (from-to)	543-548
Number of pages	5
Journal	European Journal of Endocrinology
Volume	160
Issue number	4
DOIs	https://doi.org/10.1530/EJE-08-0822
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EJE-08-0822

http://www.eje-online.org/cgi/reprint/160/4/543

Cite this

@article{e4111fb56f9c4cd7aab6eb1704249fb0,

title = "Pituitary-independent effect of octreotide on IGF1 generation",

abstract = "Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH",

author = "Ana Pokrajac and Jan Frystyk and Allan Flyvbjerg and Trainer, {Peter J.}",

year = "2009",

doi = "10.1530/EJE-08-0822",

language = "English",

volume = "160",

pages = "543--548",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "BioScientifica",

number = "4",

}

TY - JOUR

T1 - Pituitary-independent effect of octreotide on IGF1 generation

AU - Pokrajac, Ana

AU - Frystyk, Jan

AU - Flyvbjerg, Allan

AU - Trainer, Peter J.

PY - 2009

Y1 - 2009

N2 - Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH

AB - Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH

U2 - 10.1530/EJE-08-0822

DO - 10.1530/EJE-08-0822

M3 - Article

C2 - 19141605

SN - 0804-4643

VL - 160

SP - 543

EP - 548

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 4

ER -

Pituitary-independent effect of octreotide on IGF1 generation

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this